Elevated Cyclooxygenase-2 Expression Is Associated with Altered Expression of p53 and SMAD4, Amplification of HER-2/neu, and Poor Outcome in Serous Ovarian Carcinoma

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Cancer Research

• Publication date

  2004-01-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-0132-03PMID 14760075
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas.

  2003cited by this paper
• Distinct subtypes of serous ovarian carcinoma identified by p53 determination.

  2003cited by this paper
• Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma.

  2003cited by this paper
• Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer.

  2003cited by this paper
• Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies.

  2003cited by this paper
• Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.

  2002influential reference
• Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.

  2002cited by this paper
• Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.

  2002cited by this paper
• Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus.

  2002cited by this paper
• Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients.

  2002cited by this paper
• Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer

  2002cited by this paper
• Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.

  2002cited by this paper
• Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms.

  2001cited by this paper
• Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.

  2001cited by this paper
• Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer

  2001cited by this paper
• Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2

  2001cited by this paper
• Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.

  2001cited by this paper
• Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder.

  2001cited by this paper
• Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice*

  2001cited by this paper
• Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract.

  2001cited by this paper
• Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC.

  2001cited by this paper
• Carcinoma of the ovary.

  2001cited by this paper
• Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

  2001cited by this paper
• Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages.

  2001cited by this paper
• Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma.

  2001cited by this paper
• The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

  2000cited by this paper
• Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice.

  2000cited by this paper
• The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma

  2000cited by this paper
• Inhibition of Cyclooxygenase-2 Gene Expression by p53*

  1999cited by this paper
• Chromosome abnormalities in ovarian adenocarcinoma: II. prognostic impact of nonrandom chromosome abnormalities in 244 cases

  1999cited by this paper
• Genetic changes in inherited and sporadic ovarian carcinomas by comparative genomic hybridization: extensive similarity except for a difference at chromosome 2q24-q32.

  1998cited by this paper
• Overexpression of the Oncogene c‐erbB-2 (HER2/neu) and Response to Chemotherapy in Patients with Ovarian Cancer

  1998influential reference
• Tissue microarrays for high-throughput molecular profiling of tumor specimens

  1998cited by this paper
• Expression of Prostaglandin G/H Synthase Type 1, but not Type 2, in Human Ovarian Adenocarcinomas

  1998cited by this paper
• Prognostic factors in ovarian cancer.

  1998cited by this paper
• Expression of cyclooxygenase-2 in human gastric carcinoma.

  1997cited by this paper
• Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).

  1996cited by this paper
• Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer

  1996cited by this paper
• Suppression of Intestinal Polyposis in ApcΔ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)

  1996cited by this paper
• p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial overian carcinoma

  1995cited by this paper
• Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation.

  1994cited by this paper
• Prognostic significance of p53 immunostaining in epithelial ovarian cancer.

  1994cited by this paper
• Prognostic impact of chromosome aberrations in ovarian cancer.

  1992cited by this paper
• Mutation of p53 gene in hepatocellular carcinoma in Taiwan.

  1992cited by this paper
• Prognostic factors in ovarian cancer.

  1992cited by this paper
• Prognostic factors in ovarian cancer.

  1991cited by this paper
• Overexpression and mutation of p53 in epithelial ovarian cancer.

  1991cited by this paper
• Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

  1990influential reference
• [Carcinoma of the ovary].

  1960cited by this paper

• Expression of cyclooxygenase-2 (COX-2) in epithelial ovarian cancers in an Indigenous African population of Kano, Nigeria

  2025cites this paper
• GPBAR1 Promotes Proliferation of Serous Ovarian Cancer by Inducing Smad4 Ubiquitination

  2021cites this paper
• Immunology and Immunotherapy of Ovarian Cancer

  2020cites this paper
• Progesterone Receptor Serves the Ovary as a Trigger of Ovulation and a Terminator of Inflammation.

  2020cites this paper
• Lipid metabolism and Calcium signaling in epithelial ovarian cancer.

  2019cites this paper
• Prognostic and therapeutic implications of lysyl oxidase and cyclooxygenase 2 expressions in epithelial ovarian carcinoma

  2019cites this paper
• Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors

  2018cites this paper
• COX-2 expression in ovarian cancer: an updated meta-analysis

  2017cites this paper
• Post-Transcriptional Regulatory Mechanisms in the Control of Cell Identity

  2017cites this paper
• Clinico-Pathological Significances of Snail 1 & Cox 2 Co-Expression in Serous Ovarian Carcinoma

  2017cites this paper
• SKP2/P27Kip1 pathway is associated with Advanced Ovarian Cancer in Saudi Patients.

  2015cites this paper
• Synergic effect between 5‑fluorouracil and celecoxib on hypoxic gastric cancer cells.

  2015cites this paper
• Cyclooxygenase 2 promoted the tumorigenecity of pancreatic cancer cells

  2014cites this paper
• Tissue Biomarkers in Prognostication of Serous Ovarian Cancer following Neoadjuvant Chemotherapy

  2014cites this paper
• HER2, P53, FAS, FASL, COX2, PGE2S, EGFR Expression in Breast Cancer and in Normal Peritumoral Breast Tissue: Potential Novel Risk Biomarkers

  2014influential citation
• Butein induces cell apoptosis and inhibition of cyclooxygenase‑2 expression in A549 lung cancer cells.

  2014cites this paper
• Cyclo-oxygenase-2 expression in oral squamous cell carcinoma.

  2014cites this paper
• Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice

  2014cites this paper
• Silencing of cyclooxygenase-2 inhibits the growth, invasion and migration of ovarian cancer cells.

  2014cites this paper
• Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies.

  2013cites this paper
• Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cells.

  2012cites this paper
• Heparanase and cyclooxygenase-2 gene and protein expressions during progression of oral epithelial dysplasia to carcinoma.

  2012cites this paper
• Expression of COX-2 and E-cadherin in Tunisian patients with colorectal adenocarcinoma.

  2012cites this paper
• Roles of E-cadherin and cyclooxygenase enzymes in predicting different survival patterns of optimally cytoreduced serous ovarian cancer patients.

  2012cites this paper
• VIRTUAL SCREEIG AD MOLECULAR DOCKIG AALYSIS FOR PREDICTIG THE POTETIAL CYCLOOXYGEASE2 IHIBITIG DRUGS I THE TREATMET OF CACER

  2012cites this paper
• Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice.

  2012cites this paper
• Prognostic role of CIP2A expression in serous ovarian cancer

  2011cites this paper
• A comparative immunohistochemical analysis of COX-2, p53, and Ki-67 expression in keratocystic odontogenic tumors.

  2011cites this paper
• Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours

  2011cites this paper
• comparative immunohistochemical analysis of COX-2 , p 53 , and Ki-67 expression in keratocystic odontogenic tumors

  2011cites this paper
• VIRTUAL SCREE I G A D MOLECULAR DOCKI G A ALYSIS FOR PREDICTI G THE POTE TIAL CYCLOOXYGE ASE-2 I HIBITI G DRUGS I THE TREATME T OF CA CER

  2011cites this paper
• Combined Effects of Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Carcinoma in Vivo

  2011cites this paper
• Potential relevance of cyclooxygenase-2 expression in keratocystic odontogenic tumours - an immunohistochemical study.

  2011cites this paper
• Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy

  2011cites this paper
• COX-2 Expression in Nonepithelial Ovarian Malignancies

  2011cites this paper
• The role of cancer stem cells and the side population in epithelial ovarian cancer.

  2010cites this paper
• Prognostic role of Wnt7a expression in ovarian carcinoma patients.

  2010cites this paper
• Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer.

  2010cites this paper
• Cyclin D1 Expression and the Inhibitory Effect of Celecoxib on Ovarian Tumor Growth in Vivo

  2010cites this paper
• p53 and Angiogenesis

  2010cites this paper
• Pharmacological modulation and manipulation of cancer drug resistance

  2010cites this paper
• Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies

  2010cites this paper
• An overview on the expression of cyclooxygenase-2 in tumors of the head and neck.

  2009cites this paper
• Cox-2 expression in ovarian malignancies: a review of the clinical aspects.

  2009influential citation
• The Cyclooxygenase Inhibitor Sulindac Sulfide Inhibits EP4 Expression and Suppresses the Growth of Glioblastoma Cells

  2009cites this paper
• Cox-2 immunohistochemical expression in epithelial ovarian carcinoma and platin sensitivity.

  2009cites this paper
• Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas  

  2008cites this paper
• Regulation of EP4 expression via the Sp-1 transcription factor: inhibition of expression by anti-cancer agents.

  2008cites this paper
• Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer

  2008cites this paper
• Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer.

  2008cites this paper
• Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo

  2008cites this paper
• The prognostic significance of COX-2 and survivin expression in ovarian cancer.

  2008cites this paper
• GENOMIC AND TRANSCRIPTOME PROFILING OF EPITHELIAL OVARIAN CANCER

  2008cites this paper
• UTILISATION DES ANTI-INFLAMMATOIRES NON STEROÏDIENS EN CHIMIOTHERAPIE ANTI-CANCEREUSE : ACTUALITES

  2008cites this paper
• Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma.

  2007cites this paper
• Role of the endothelins and endothelin receptors in cancer cell signaling and angiogenesis

  2007cites this paper
• HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients

  2007cites this paper
• Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic.

  2007cites this paper
• Tumour–host interactions: implications for developing anti-cancer therapies

  2006cites this paper
• Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions.

  2006cites this paper
• Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer

  2006cites this paper
• Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer

  2006cites this paper
• The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer

  2006cites this paper
• OPCML and the IgLON family : expression, function and links with ovarian cancer

  2006cites this paper
• Genomic tests for ovarian cancer detection and management.

  2006cites this paper
• Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression

  2006cites this paper
• Prognostic tumour markers in pancreatic cancer

  2006cites this paper
• Expression of peroxisome proliferator activated receptor γ and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma

  2006cites this paper
• Cyclooxygenase-2 expression in squamous cell carcinoma of the oral cavity and pharynx: association to p53 and clinical outcome.

  2006cites this paper
• Prognostic significance of cyclooxygenase-2 in breast and esophageal carcinoma

  2005cites this paper
• Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression

  2005cites this paper
• Effects of PGF2alpha on human melanocytes and regulation of the FP receptor by ultraviolet radiation.

  2005cites this paper
• Mechanisms and markers of carcinogenesis and neoplastic progression

  2005cites this paper
• Emerging role of the endothelin axis in ovarian tumor progression.

  2005cites this paper
• Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma.

  2005cites this paper
• Cox-2 and Her2/neu co-expression in invasive bladder cancer.

  2005cites this paper
• Cáncer de ovario

  2005cites this paper
• Prognostic role of cyclooxygenase‐2 in neoadjuvant‐treated patients with squamous cell carcinoma of the esophagus

  2005influential citation
• Biological characterization of ovarian cancer: prognostic and therapeutic implications.

  2005cites this paper
• Prognosis of Papillary Thyroid Cancer

  2005cites this paper
• Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.

  2005cites this paper
• The development of new treatment strategies for oesophageal cancer

  2004cites this paper
• Cyclooxygenase-2 Expression

  2004cites this paper
• Endothelin-1-induced Prostaglandin E2-EP2, EP4 Signaling Regulates Vascular Endothelial Growth Factor Production and Ovarian Carcinoma Cell Invasion*

  2004cites this paper
• Cyclooxygenase-2 Expression : A Significant Prognostic Indicator for Patients With Colorectal Cancer Labile

  2004cites this paper
• Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells

  2004cites this paper
• Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma.

  2003cites this paper